Processa Pharmaceuticals, Inc. (PCSA)
Chart Events
Performance Outlook
| Previous Close | 0.4514 |
| Open | 0.4700 |
| Bid | 0.4403 x 900 |
| Ask | 0.4490 x 800 |
| Day's Range | 0.4001 - 0.4725 |
| 52 Week Range | 0.3850 - 4.0100 |
| Volume | |
| Avg. Volume | 295,993 |
| Market Cap | 10.524M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings Date | Mar 28, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PCSA
Related Research
- Processa Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 10/21/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- GlobeNewswire
Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative.Patients treated with Next Generation Chemotherapy-Capecitabine have NOT had hand-foot syndrome or cardiotoxicity adverse events, typically seen in 50-70% of patients presently on FDA-approved capecitabine.In mid-April Processa expects guidance from FDA on our Phase 2B trial design and our Project Optimus appr
- GlobeNewswire
Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
HANOVER, MD, March 07, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that the Company’s President & CEO, Dr. David Young, will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:00 PM Eastern. The company is looking forward to
- GlobeNewswire
Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
Our Next Generation Chemotherapies (NGCs) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug has been altered to provide potentially safer and more effective chemotherapy to cancer patients.Based on preliminary clinical and pre-clinical studies, more cancer patients should benefit from our NGCs than their FDA-approved counterpart drugs.Our Regulatory Science approach, encompassing the principles of FDA’s Project Optimus and Oncology Guidance, should increase t
